ProfileGDS5678 / 1418860_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 72% 70% 71% 71% 77% 68% 70% 76% 69% 72% 71% 72% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5845872
GSM967853U87-EV human glioblastoma xenograft - Control 24.5474272
GSM967854U87-EV human glioblastoma xenograft - Control 34.3221570
GSM967855U87-EV human glioblastoma xenograft - Control 44.5350871
GSM967856U87-EV human glioblastoma xenograft - Control 54.4859871
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1549877
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1881668
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4073670
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0774576
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2665869
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5322472
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.5343871
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6054872
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5377172